Dr Gillmore is an internationally recognised scientist who is famous for his persistent work in the field of amyloidosis. He has specialised in this area during his MD and PhD programmes which were completed at Imperial College London (2001) and University College London (UCL, 2004), respectively. During his time at university, Dr. Gillimore did laboratory-based research on the “Studies of serum amyloid P component and antinuclear autoimmunity” as well as a clinical MD entitled: “Characterisation and treatment of hereditary and acquired systematic amyloidosis”. During his extensive career, he has worked at some of the most prestigious research centres in the world, including the Royal Free Campus and the National Amyloidosis Centre, UK. Dr. Gullmore is currently the Centre Head at the Centre for Amyloidosis and Acute Phase Proteins at UCL and a Prof. of Medicine & Honorary Consultant Nephrologist. Additionally, he has been a Reader and Honorary Consultant Nephrologist (2012-2017) where he continued spreading awareness and contributing to the fight against Amyloidosis.
He has developed a network of haematologists across the UK who have an interest in treating patients with the most common form of amyloidosis: AL type. Dr. Gullimore’s commitment to finding a cure led him to undertake the first randomized controlled trial of treatment in this most serious disease (AL type). He has worked closely with the UK Myeloma Forum and leaders in haematological cancer to achieve this difficult goal. Additionally, he has been involved in the foundation of a patient support group and was chair and principal author of the British Guidelines on the management of AL Amyloidosis (published in 2013).
Dr. Gillmore was the first scientist to systematically highlight the relationship between the abundance of amyloid fibril precursor proteins, the course of amyloid deposits and the clinical outcome in several different forms of Amyloidosis. His widely cited seminal paper published in the Lancet (2001) had a major impact on management of AA amyloidosis and amyloidosis generally. Among his publications, which were cited more than 15,000 times, is the study of: “Cardiac structural and functional consequences of amyloid deposition by cardiac magnetic resonance and echocardiography and their prognostic roles” which was first issued at the International Journal of Cardiovascular Imaging.
He has been involved in the development of many of the advances in therapy for systemic AL amyloidosis including novel chemotherapy regimens (CTD, bortezomib, and stem cell transplantation) and transplantation (cardiac and renal) over recent years. The survival of systemic AL amyloidosis has steadily improved due to these advancements. He has also made critical contributions to the evaluation and publication of the first recipients of orthotopic liver transplants as curative ‘surgical gene therapy’ in several hereditary forms of amyloidosis.
